1. Caudill-Slosberg MA, Schwartz LM, Woloshin S. Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs. 2000. Pain. 2004; 109: 514-9.
2. Australian Institute of Health and Welfare. Statistics on drug use in Australia 2002. Canberra: Australian Institute of Health and Welfare, 2003.
4. Macintyre PE, Jarvis DA. Age is the best predictor of postoperative morphine requirements. Pain. 1996; 64: 357-64.
5. Australian and New Zealand College of Anaesthetists. Acute pain management: scientific evidence. Melbourne: Australian and New Zealand College of Anaesthetists, 2005.
6. Ballantyne JC. Chronic pain following treatment for cancer: the role of opioids. Oncologist. 2003; 8: 567-75.
7. Breivik H. Opioids in cancer and chronic non-cancer pain therapy-indications and controversies. Acta Anaesthesiologica Scandinavica. 2001; 45: 1059-66.
8. Mercadante S, Portenoy RK. Opioid poorly-responsive cancer pain. Part 1: clinical considerations. Journal of Pain and Symptom Management. 2001; 21: 144-50.
9. Graziotti PJ, Goucke CR. The use of oral opioids in patients with chronic non-cancer pain. Management strategies. Medical Journal of Australia. 1997; 167: 30-4.
10. Kalso E, Allan L, Dellemijn PL et al. Recommendations for using opioids in chronic non-cancer pain. European Journal of Pain. 2003; 7: 381-6.
11. Anonymous. Recommendations for the appropriate use of opioids for persisitent non-cancer pain. 2004. Accessed 13 November 2006. Available from: www.britishpainsociety.org/opioids_doc_2004.pdf
* 12. Trescot AM, Boswell MV, Atluri SL et al. Opioid guidelines in the management of chronic non-cancer pain. Pain Physician. 2006; 9: 1-39.
13. Eriksen J, Sjogren P, Bruera E et al. Critical issues on opioids in chronic non-cancer pain: an epidemiological study. Pain. 2006; 125: 172-9.
* 14. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004; 112: 372-80.
* 15. Eisenberg E, McNicol ED, Carr DB. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-analysis of randomized controlled trials. Journal of the American Medical Association 2005; 293: 3043-52.
* 16. Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. Canadian Medical Association Journal. 2006; 174: 1589-94.
17. Maier C, Hildebrandt J, Klinger R et al. Morphine responsiveness, efficacy and tolerability in patients with chronic non-tumor associated pain - results of a doubleblind placebo-controlled trial (MONTAS). Pain. 2002; 97: 223-33.
18. Watson CP, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology. 1998; 50: 1837-41.
* 19. Watson CP, Moulin D, Watt-Watson J et al. Controlled-
release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy Pain. 2003; 105: 71-8.
* 20. Chou R, Clark E, Helfand M. Comparative efficacy and safety of long-acting oral opioids for chronic non-cancer pain: a systematic review. Journal of Pain and Symptom Management. 2003; 26: 1026-48.
21. Allan L, Hays H, Jensen NH et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. British Medical Journal 2001; 322: 1154-8.
22. Caldwell JR, Rapoport RJ, Davis JC et al. Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial. Journal of Pain and Symptom Management. 2002; 23: 278-91.
23. Griessinger N, Sittl R, Likar R. Transdermal buprenorphine in clinical practice - a post-marketing surveillance study in 13,179 patients. Current Medical Research and Opinion. 2005; 21: 1147-56.
24. Radbruch L, Sabatowski R, Petzke F et al. Transdermal fentanyl for the management of cancer pain: a survey of 1005 patients. Palliative Medicine. 2001; 15: 309-21.
25. Shipton E. Safety and tolerability of buprenorphine. In: Budd KRR (ed.). Basic pharmacology of buprenorphine. Stuttgart: Georg Thieme Verlag, 2005: 102-15.
* 26. Sittl R, Nuijten M, Nautrup BP. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study. Clinical Therapy. 2005; 27: 1022-31.
27. Allan L, Richarz U, Simpson K, Slappendel R. Transdermal fentanyl versus sustained release oral morphine in strong-opioid naive patients with chronic low back pain. Spine. 2005; 30: 2484-90.
* 28. Clark AJ, Ahmedzai SH, Allan LG et al. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. Current Medical Research and Opinion. 2004; 20: 1419-28.
* 29. Sandoval JA, Furlan AD, Mailis-Gagnon A. Oral methadone for chronic noncancer pain: a systematic literature review of reasons for administration, prescription patterns, effectiveness, and side effects. Clinical Journal of Pain. 2005; 21: 503-12.
30. Morley JS, Bridson J, Nash TP et al. Low-dose methadone has an analgesic effect in neuropathic pain: a doubleblind randomized controlled crossover trial. Palliative Medicine. 2003; 17: 576-87.
* 31. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clinical Trials. 1996; 17: 1-12.
32. Gorman AL, Elliott KJ, Inturrisi CE. The d- and l-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neuroscience Letters. 1997; 223: 5-8.
33. Fainsinger R, Schoeller T, Bruera E. Methadone in the management of cancer pain: a review. Pain. 1993; 52: 137-47.
34. Fredheim OM, Borchgrevink PC, Klepstad P et al. Long term methadone for chronic pain: A pilot study of pharmacokinetic aspects. European Journal of Pain. 2007; 11: 599-604.
35. Gourlay G (ed.). Different opioids - same actions. In: Kalso EMH, Weisenfeld-Hallin Z (eds). Progress in pain research and management 14. Seattle, WA: IASP Press, 1991.
36. Ripamonti C, Groff L, Brunelli C et al. Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? Journal of Clinical Oncology. 1998; 16: 3216-21.
37. Toombs JD, Kral LA. Methadone treatment for pain states. American Family Physician. 2005; 71: 1353-8.
38. Cooper GA, Seymour A, Cassidy MT, Oliver JS. A study of methadone in fatalities in the Strathclyde Region, 1991-1996. Medicine, Science, and the Law. 1999; 39: 233-42.
39. Caplehorn JR, Drummer OH. Fatal methadone toxicity: signs and circumstances, and the role of benzodiazepines. Australian and New Zealand Journal of Public Health. 2002; 26: 358-62; discussion 62-3.
40. Milroy CM, Forrest AR. Methadone deaths: a toxicological analysis. Journal of Clinical Pathology. 2000; 53: 277-81.
41. Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology. 2003; 60: 927-34.
42. Moulin DE, Iezzi A, Amireh R et al. Randomised trial of oral morphine for chronic non-cancer pain. Lancet. 1996; 347: 143-7.
43. Langford R, McKenna F, Ratcliffe S et al. Transdermal fentanyl for improvement of pain and functioning in osteoarthritis: a randomized, placebo-controlled trial. Arthritis and Rheumatism. 2006; 54: 1829-37.
44. Cowan A FE, Strassburger W, Rafa RB. Basic pharmacology of buprenorphine. In: Budd KRR (ed.). Buprenorphine - the unique opioid analgesic. Pharmacology and clinical application. Stuttgart: Georg Thieme Verlag, 2005: 3-21.
45. Likar R, Kayser H, Sittl R. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials. Clinical Therapy. 2006; 28: 943-52.
46. Sittl R. Transdermal buprenorphine in the treatment of chronic pain. Expert Review of Neurotherapeutics. 2005; 5: 315-23.
47. Sorge J, Sittl R. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Clinical Therapy. 2004; 26: 1808-20.
48. Mercadante S, Villari P, Ferrera P et al. Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine. Journal of Pain and Symptom Management. 2006; 32: 175-9.
49. Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Archives of General Psychiatry. 1978; 35: 501-16.
50. Murphy EJ. Acute pain management pharmacology for the patient with concurrent renal or hepatic disease. Anaesthesia and Intensive Care. 2005; 33: 311-22.
51. Filitz J, Griessinger N, Sittl R et al. Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine. European Journal of Pain. 2006; 10: 743-8.
52. Dahan A. Opioid-induced respiratory effects: new data on buprenorphine. Palliative Medicine. 2006; 20 (Suppl. 1): s3-8.
* 53. Finnerup NB, Otto M, McQuay HJ et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain. 2005; 118: 289-305.
54. Schug SA. Combination analgesia in 2005 - a rational approach: focus on paracetamol-tramadol. Clinical Rheumatology. 2006; 25 (Suppl. 7): 16-21.
55. Cepeda MS, Camargo F, Zea C, Valencia L. Tramadol for osteoarthritis. Cochrane Database of Systematic Reviews. 2006; CD005522.
56. Preston KL, Jasinski DR, Testa M. Abuse potential and pharmacological comparison of tramadol and morphine. Drug and Alcohol Dependence. 1991; 27: 7-17.
57. Adams EH, Breiner S, Cicero TJ et al. A comparison of the abuse liability of tramadol, NSAIDs, and hydrocodone in patients with chronic pain. Journal of Pain and Symptom Management. 2006; 31: 465-76.
58. Labate A, Newton MR, Vernon GM, Berkovic SF. Tramadol and new-onset seizures. Medical Journal of Australia. 2005; 182: 42-3.
59. Kitson R, Carr B. Tramadol and severe serotonin syndrome. Anaesthesia. 2005; 60: 934-5.
* 60. Cowan DT, Wilson-Barnett J, Griffiths P, Allan LG. A survey of chronic noncancer pain patients prescribed opioid analgesics. Pain Medicine. 2003; 4: 340-51.
61. Cowan DT, Wilson-Barnett J, Griffiths P et al. A
randomized, double-blind, placebo-controlled, cross-over pilot study to assess the effects of long-term opioid drug consumption and subsequent abstinence in chronic noncancer pain patients receiving controlled-release morphine. Pain Medicine. 2005; 6: 113-21. Oxford league table of analgesic efficacy. Accessed November 26, 2006. Available from: www.jr2.ox.ac.uk/ bandolier/booth/painpag/Acutrev/Analgesics/Leagtab.html Elia N, Lysakowski C, Tramer MR. Does multimodal analgesia with acetaminophen, nonsteroidal antiinflammatory drugs, or selective cyclooxygenase-2 inhibitors and patient-controlled analgesia morphine offer advantages over morphine alone? Meta-analyses of randomized trials. Anesthesiology 2005; 103: 1296-304.
64. Romsing J, Moiniche S, Mathiesen O, Dahl JB. Reduction of opioid-related adverse events using opioid-sparing analgesia with COX-2 inhibitors lacks documentation: a systematic review. Acta Anaesthesiologica Scandinavica. 2005; 49: 133-42.
65. McNicol E, Strassels SA, Goudas L et al. NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database of Systematic Reviews. 2005: CD005180.
66. Palangio M, Damask MJ, Morris E et al. Combination hydrocodone and ibuprofen versus combination codeine and acetaminophen for the treatment of chronic pain. Clinical Therapy. 2000; 22: 879-92.
67. Palangio M, Morris E, Doyle Jr RT et al. Combination hydrocodone and ibuprofen versus combination
oxycodone and acetaminophen in the treatment of moderate or severe acute low back pain. Clinical Therapy. 2002; 24: 87-99.
Mullican WS, Lacy JR. Tramadol/acetaminophen combination tablets and codeine/acetaminophen combination capsules for the management of chronic pain: a comparative trial. Clinical Therapy. 2001; 23: 1429-45.
Ruoff GE, Rosenthal N, Jordan D et al. Tramadol/ acetaminophen combination tablets for the treatment of chronic lower back pain: a multicenter, randomized, double-blind, placebo-controlled outpatient study. Clinical Therapy. 2003; 25: 1123-41.
Peloso PM, Fortin L, Beaulieu A et al. Analgesic efficacy and safety of tramadol/acetaminophen combination tablets (Ultracet) in treatment of chronic low back pain: a multicenter, outpatient, randomized, double blind, placebo controlled trial. Journal of Rheumatology. 2004; 31: 2454-63.
Bennett RM, Kamin M, Karim R, Rosenthal N. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. American Journal of Medicine. 2003; 114: 537-45.
Caldwell JR, Hale ME, Boyd RE et al. Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: a double blind, randomized, multicenter, placebo controlled trial. Journal of Rheumatology. 1999; 26: 862-9. Johnson RE, Fudala PJ, Payne R. Buprenorphine: considerations for pain management. Journal of Pain and Symptom Management. 2005; 29: 297-326.
* 74. Hurley RW, Cohen SP, Williams KA et al. The analgesic effects of perioperative gabapentin on postoperative pain: a meta-analysis. Regional Anesthesia and Pain Medicine. 2006; 31: 237-47.
Ho KY, Gan TJ, Habib AS. Gabapentin and postoperative pain - a systematic review of randomized controlled trials. Pain. 2006; 126: 91-101.
Eckhardt K, Ammon S, Hofmann U et al. Gabapentin enhances the analgesic effect of morphine in healthy volunteers. Anesthesia and Analgesia. 2000; 91: 185-91.
Subramaniam K, Subramaniam B, Steinbrook RA. Ketamine as adjuvant analgesic to opioids: a quantitative and qualitative systematic review. Anesthesia and Analgesia. 2004; 99: 482-95.
* 78. Visser E, Schug SA. The role of ketamine in pain management. Biomedicine and Pharmacotherapy. 2006; 60: 341-8.
Somogyi A, White J. Opioid-induced hyperalgesia: implications for pain management in the opioid-dependent subject. 11th World Congress on Pain. Sydney. Seattle: IASP Press, 2005.
Kocabas S, Karaman S, Uysallar E, Firat V. The use of tramadol and morphine for pain relief after abdominal
hysterectomy. Clinical and Experimental Obstetrics and 96.
Gynecology. 2005; 32: 45-8.
81. Webb AR, Leong S, Myles PS, Burn SJ. The addition of a tramadol infusion to morphine patient-controlled analgesia after abdominal surgery: a double-blinded, 97.
placebo-controlled randomized trial. Anesthesia and Analgesia. 2002; 95: 1713-8.
82. Ngan Kee WD, Khaw KS, Wong EL. Randomised double- 98. blind comparison of morphine vs. a morphine-alfentanil combination for patient-controlled analgesia.
Anaesthesia. 1999; 54: 629-33.
83. Mercadante S, Villari P, Ferrera P, Casuccio A. Addition of a 99. second opioid may improve opioid response in cancer pain: preliminary data. Supportive Care in Cancer. 2004; 12:
84. Smith MT, de la Iglesia FA. Co-administration of oxycodone and morphine and analgesic synergy reexamined. British Journal of Clinical Pharmacology. 2005; 59: 486-7; author reply 7-8.
85. Chindalore VL, Craven RA, Yu KP et al. Adding ultralow- 101. dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex. Journal of Pain. 2005; 6: 392-9.
86. Ross FB, Wallis SC, Smith MT. Co-administration of sub- 102. antinociceptive doses of oxycodone and morphine produces marked antinociceptive synergy with reduced CNS side-effects in rats. Pain. 2000; 84: 421-8.
87. He L, Whistler JL. An opiate cocktail that reduces 103. morphine tolerance and dependence. Current Biology.
* 88. Gustorff B. Intravenous opioid testing in patients with 104.
chronic non-cancer pain. European Journal of Pain. 2005; 9: 123-5.
89. Eisenberg E, McNicol E, Carr DB. Opioids for neuropathic pain. Cochrane Database of Systematic Reviews. 2006; 105.
* 90. Dellemijn PL, van Duijn H, Vanneste JA. Prolonged 106.
treatment with transdermal fentanyl in neuropathic pain. Journal of Pain and Symptom Management. 1998; 16: 220-9.
91. Attal N, Guirimand F, Brasseur L et al. Effects of IV
morphine in central pain: a randomized placebo- 107.
controlled study. Neurology. 2002; 58: 554-63.
* 92. Nicholas MK, Molloy AR, Brooker C. Using opioids with persisting noncancer pain: a biopsychosocial perspective. 108.
Clinical Journal of Pain. 2006; 22: 137-46.
* 93. Waddell G, Pilowsky I, Bond MR. Clinical assessment and interpretation of abnormal illness behaviour in low back 109.
94. Wu SM, Compton P, Bolus R et al. The addiction behaviors checklist: validation of a new clinician-based measure of 110. inappropriate opioid use in chronic pain. Journal of Pain and Symptom Management. 2006; 32: 342-51. 111.
95. Akbik H, Butler SF, Budman SH et al. Validation and clinical application of the Screener and Opioid Assessment for Patients with Pain (SOAPP). Journal of Pain and Symptom Management. 2006; 32: 287-93.
Moore RA, McQuay HJ. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. Arthritis Research and Therapy. 2005; 7: R1046-51.
Vainio A, Ollila J, Matikainen E et al. Driving ability in cancer patients receiving long-term morphine analgesia. Lancet. 1995; 346: 667-70.
Haythornthwaite JA, Menefee LA, Quatrano-Piacentini AL, Pappagallo M. Outcome of chronic opioid therapy for noncancer pain. Journal of Pain and Symptom Management. 1998; 15: 185-94.
Budd RD, Muto JJ, Wong JK. Drugs of abuse found in fatally injured drivers in Los Angeles County. Drug and Alcohol Dependence. 1989; 23: 153-8. Gaertner J, Radbruch L, Giesecke T et al. Assessing cognition and psychomotor function under long-term treatment with controlled release oxycodone in noncancer pain patients. Acta Anaesthesiologica Scandinavica. 2006; 50: 664-72. Menefee LA, Frank ED, Crerand C et al. The effects of transdermal fentanyl on driving, cognitive performance, and balance in patients with chronic nonmalignant pain conditions. Pain Medicine. 2004; 5: 42-9. Wei G, Moss J, Yuan CS. Opioid-induced immunosuppression: is it centrally mediated or peripherally mediated? Biochemical Pharmacology. 2003; 65: 1761-6.
Roberts LJ, Finch PM, Pullan PT et al. Sex hormone suppression by intrathecal opioids: a prospective study. Clinical Journal of Pain. 2002; 18: 144-8. Abs R, Verhelst J, Maeyaert J et al. Endocrine consequences of long-term intrathecal administration of opioids. Journal of Clinical Endocrinology and Metabolism. 2000; 85: 2215-22.
Daniell HW. Hypogonadism in men consuming sustained-action oral opioids. Journal of Pain. 2002; 3: 377-84. Fredheim OM, Borchgrevink PC, Hegrenaes L et al. Opioid switching from morphine to methadone causes a minor but not clinically significant increase in QTc time: A prospective 9-month follow-up study. Journal of Pain and Symptom Management. 2006; 32: 180-5. Medsafe. Cardiac vigilance recommended for methadone. 2005; Accessed November 29, 2006. Available from: www.medsafe.govt.nz/profs/puarticles/methadone.htm. Fishbain DA, Rosomoff HL, Rosomoff RS. Drug abuse, dependence, and addiction in chronic pain patients. Clinical Journal of Pain. 1992; 8: 77-85. Cowan DT, Allan LG, Libretto SE, Griffiths P. Opioid drugs: a comparative survey of therapeutic and "street" use. Pain Medicine. 2001; 2: 193-203.
Collett BJ. Chronic opioid therapy for non-cancer pain. British Journal of Anaesthesia. 2001; 87: 133-43. Maier C, Schaub C, Willweber-Strumpf A, Zenz M. [Long-term efficiency of opioid medication in patients with chronic non-cancer-associated pain. Results of a survey 5 years after onset of medical treatment]. Schmerz. 2005; 19: 410-7.
112. Zenz M, Strumpf M, Tryba M. Long-term oral opioid therapy in patients with chronic nonmalignant pain. Journal of Pain and Symptom Management. 1992; 7: 4129.
4113. Jensen MK, Thomsen AB, Hojsted J. 10-year follow-up of chronic non-malignant pain patients: opioid use, health 130.
related quality of life and health care utilization. European Journal of Pain. 2006; 10: 423-33. 114. Mercadante S, Dardanoni G, Salvaggio L et al. Monitoring 4131. of opioid therapy in advanced cancer pain patients. Journal of Pain and Symptom Management. 1997; 13: 204-12. 132.
*115. Buntin-Mushock C, Phillip L, Moriyama K, Palmer PP. Age-dependent opioid escalation in chronic pain patients. Anesthesia and Analgesia. 2005; 100: 1740-5. 133.
4=116. Milligan K, Lanteri-Minet M, Borchert K et al. Evaluation of long-term efficacy and safety of transdermal fentanyl in the treatment of chronic noncancer pain. Journal of Pain. 2001; 2:197-204. 134.
117. Mystakidou K, Parpa E, Tsilika E et al. Long-term management of noncancer pain with transdermal therapeutic system-fentanyl. Journal of Pain. 2003; 4:
118. Sloan P, Melzack R. Long-term patterns of morphine dosage and pain intensity among cancer patients. Hospice Journal. 1999; 14: 35-47.
4119. Ballantyne JC, Mao J. Opioid therapy for chronic pain. New 136. England Journal of Medicine. 2003; 349: 1943-53.
4120. Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology. 2006; 104:
121. Guignard B, Bossard AE, Coste C et al. Acute opioid tolerance: intraoperative remifentanil increases postoperative pain and morphine requirement. 138.
Anesthesiology. 2000; 93: 409-17.
122. Chu LF, Clark DJ, Angst MS. Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study.
4123. Athanasos P, Smith CS, White JM et al. Methadone maintenance patients are cross-tolerant to the antinociceptive effects of very high plasma morphine concentrations. Pain. 2006; 120: 267-75.
124. South SM, Smith MT. Analgesic tolerance to opioids. Pain 140. Clinical Updates. 2001; IX: 5 (accessed at wwwiasp-painorg/PCU01-5html).
125. Simonnet G, Rivat C. Opioid-induced hyperalgesia: 141. abnormal or normal pain? Neuroreport. 2003; 14: 1-7.
126. Doverty M, White JM, Somogyi AA et al. Hyperalgesic responses in methadone maintenance patients. Pain.
4127. Thomsen AB, Becker N, Eriksen J. Opioid rotation in chronic non-malignant pain patients. A retrospective study. Acta Anaesthesiologica Scandinavica. 1999; 43: 143.
128. Woodhouse A, Ward ME, Mather LE. Intra-subject 144.
variability in post-operative patient-controlled analgesia
(PCA): is the patient equally satisfied with morphine, pethidine and fentanyl? Pain. 1999; SO: 545-53. Quigley C. Opioid switching to improve pain relief and drug tolerability. Cochrane Database of Systematic Reviews. 2004; CD004S47.
Berger A, Hoffman DL, Goodman S et al. Therapy switching in patients receiving long-acting opioids. Annals of
Pharmacotherapy. 2004; 3S: 389-95.
Kalso E, Vainio A. Morphine and oxycodone hydrochloride in the management of cancer pain. Clinical Pharmacology and Therapeutics. 1990; 47: 639-46.
Pasternak GW. Incomplete cross tolerance and multiple mu opioid peptide receptors. Trends in Pharmacological
Yaksh TL, Harty GJ. Pharmacology of the allodynia in rats evoked by high dose intrathecal morphine. Journal of Pharmacology and Experimental Therapeutics. 1988; 244: 501-07.
Enting RH, Oldenmenger WH, van der Rijt CC et al. A prospective study evaluating the response of patients with unrelieved cancer pain to parenteral opioids. Cancer. 2002; 94: 3049-56.
Pereira J, Lawlor P, Vigano A et al. Equianalgesic dose ratios for opioids a critical review and proposals for long-term dosing. Journal of Pain and Symptom Management. 2001; 22: 672-87.
Auret K, Goucke CR, Ilett KF et al. Pharmacokinetics and pharmacodynamics of methadone enantiomers in hospice patients with cancer pain. Therapeutic Drug Monitoring. 2006; 2S: 359-66.
Ayonrinde OT, Bridge DT. The rediscovery of methadone for cancer pain management. Medical Journal of Australia. 2000; 173: 536-40.
Fredheim OM, Kaasa S, Dale O et al. Opioid switching from oral slow release morphine to oral methadone may improve pain control in chronic non-malignant pain: a nine-month follow-up study. Palliative Medicine. 2006; 20: 35-41.
Portenoy R. Clinical strategies for the management of cancer pain poorly responsive to systemic opioid therapy. In: Giamberardino M (ed.). An updated review. Refresher Course Syllabus of the 10th World Congress on Pain. Seattle: IASP Press, 2002: 19-27. Mercadante S, Bruera E. Opioid switching: a systematic and critical review. Cancer Treatment Reviews. 2006; 32: 304-15.
de Stoutz ND, Bruera E, Suarez-Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. Journal of Pain and Symptom Management. 1995; 10: 378-84.
Grilo RM, Bertin P, Scotto di Fazano C et al. Opioid rotation in the treatment of joint pain. A review of 67 cases. Joint, Bone, Spine. 2002; B9: 491-4. McQuay HJ, Jadad AR. Incident pain. Cancer Surveys. 1994; 21: 17-24.
Portenoy RK, Bennett DS, Rauck R et al. Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain. Journal of Pain. 2006; 7: 583-91.
145. Svendsen KB, Andersen S, Arnason S et al. Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. European Journal of Pain. 2005; 9: 195-206.
146. Zeppetella G, O'Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in patients with non-malignant terminal disease admitted to a hospice. Palliative Medicine. 2001; 15: 243-6.
*147. Mercadante S, Villari P, Ferrera P et al. Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose. Journal of Pain and Symptom Management. 2004; 27: 352-9.
148. Carr DB, Goudas LC, Denman WT et al. Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study. Pain. 2004; 10S: 17-27.
149. Fishman SM, Bandman TB, Edwards A, Borsook D. The opioid contract in the management of chronic pain. Journal of Pain and Symptom Management. 1999; 18: 27-37.
150. Gitlin MC. Contracts for opioid administration for the management of chronic pain: a reappraisal. Journal of Pain and Symptom Management. 1999; 18: 6-8.
151. Horning MR. Chronic opioids: a reassessment. Alaska Medicine. 1997; 39: 103-10, 20.
152. Portenoy RK. Opioid therapy for chronic nonmalignant pain: a review of the critical issues. Journal of Pain and Symptom Management. 1996; 11: 203-17.
153. Bendtsen P, Hensing G, Ebeling C, Schedin A. What are the qualities of dilemmas experienced when prescribing opioids in general practice? Pain. 1999; 82: 89-96.
Was this article helpful?
It's time for a change. Finally A Way to Get Pain Relief for Your Arthritis Without Possibly Risking Your Health in the Process. You may not be aware of this, but taking prescription drugs to get relief for your Arthritis Pain is not the only solution. There are alternative pain relief treatments available.